The European Medicine Agency has recommended marketing authorization for a hybrid colchicine medicine for secondary prevention of atherothrombotic events in adults with stable coronary disease.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/eu-supports-anti-inflammatory-secondary-heart-risk-2026a1000hbs?src=rss
Author :
Publish date : 2026-05-26 15:18:00
Copyright for syndicated content belongs to the linked Source.
